Lakewood-Amedex Biotherapeutics Inc. (LABT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 24, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LABT SEC filings page.
This page shows Lakewood-Amedex Biotherapeutics Inc. (LABT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Negative equity and a thin current ratio define a balance sheet dominated by obligations rather than operating performance.
At FY2025, liabilities of$2.4M were roughly five times assets of$482K , pointing to a balance sheet financed primarily by obligations. Reported equity was negative at-$2.0M , while revenue and cash-flow measures are unavailable, so operating performance cannot be inferred from this filing snapshot.
Current assets of
The negative debt-to-equity ratio of -1.2x is mathematically driven by negative equity, so it should not be read as conventional leverage. With no reported revenue, profitability, or cash-flow figures, the available evidence is concentrated in solvency structure rather than business momentum.
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
Lakewood-Amedex Biotherapeutics Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Lakewood-Amedex Biotherapeutics Inc.'s EBITDA was -$3.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 495.5% from the same quarter a year earlier. Against the prior quarter it is down 327.8%.
Lakewood-Amedex Biotherapeutics Inc. reported -$3.8M in net income in Q2 2026. This represents a decrease of 475.1% from the same quarter a year earlier. Against the prior quarter it is down 308.5%.
Lakewood-Amedex Biotherapeutics Inc. earned -$2.75 per diluted share (EPS) in Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Lakewood-Amedex Biotherapeutics Inc. held $2.6M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Lakewood-Amedex Biotherapeutics Inc.'s ROE was -87.1% in Q2 2026, measuring profit generated per dollar of shareholder equity.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Lakewood-Amedex Biotherapeutics Inc. invested $503K in research and development in Q2 2026. This represents an increase of 242.4% from the same quarter a year earlier. Against the prior quarter it is up 176.2%.
Not reported for Q2 2026.
Not reported for Q2 2026.
LABT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|
| Cost of Revenue | N/A | $507K | N/A | N/A | N/A |
| R&D Expenses | $503K+242.4% | $182K+7.3% | N/A | $147K | $170K |
| SG&A Expenses | $3.3M+571.4% | $703K+89.2% | N/A | $489K | $372K |
| Operating Income | -$3.8M-494.6% | -$887K-63.4% | N/A | -$637K | -$543K |
| EBITDA | -$3.8M-495.5% | -$886K-63.6% | N/A | -$636K | -$541K |
| Interest Expense | $11K-55.6% | $38K+2806.4% | N/A | $24K | $1K |
| Net Income | -$3.8M-475.1% | -$923K-71.1% | N/A | -$656K | -$540K |
| EPS (Basic) | -$2.75-65.7% | -$0.20-33.3% | N/A | -$1.66 | -$0.15 |
| EPS (Diluted) | -$2.75 | -$0.20-33.3% | N/A | -$1.66 | -$0.15 |
| Diluted Shares (Avg) | 1M | 7M+0.7% | N/A | 694,450 | 7M |
Not reported in any period shown, so not listed: Revenue, Gross Profit, Income Tax.
LABT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|
| Total Assets | $5.0M | $196K | $482K | N/A | N/A |
| Current Assets | $4.8M | $51K | $305K | N/A | N/A |
| Cash & Equivalents | $2.6M+103.8% | $12K-97.5% | $236K | $1.3M | $477K |
| Short-Term Investments | $2.0M | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $629K | $3.0M | $2.4M | N/A | N/A |
| Current Liabilities | $629K | $3.0M | $2.4M | N/A | N/A |
| Non-Current Liabilities | $0 | $10K | $41K | N/A | N/A |
| Total Equity | $4.3M+733.9% | -$2.8M-3627.6% | -$2.0M | -$683K | -$76K |
| Retained Earnings | -$68.6M | -$54.3M | -$53.4M | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
LABT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$2.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.13), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Lakewood-Amedex Biotherapeutics Inc. Ranks
Frequently Asked Questions
What are Lakewood-Amedex Biotherapeutics Inc.'s total assets?
Lakewood-Amedex Biotherapeutics Inc. (LABT) had $482K in total assets as of fiscal year 2025, including both current and long-term assets.
What is Lakewood-Amedex Biotherapeutics Inc.'s current ratio?
Lakewood-Amedex Biotherapeutics Inc. (LABT) had a current ratio of 0.13 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Lakewood-Amedex Biotherapeutics Inc.'s P/E ratio?
Lakewood-Amedex Biotherapeutics Inc. (LABT) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $4.2M as of Sep 24, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Lakewood-Amedex Biotherapeutics Inc.'s price-to-sales ratio?
Lakewood-Amedex Biotherapeutics Inc. (LABT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $4.2M as of Sep 24, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Lakewood-Amedex Biotherapeutics Inc.'s debt-to-equity ratio negative or not reported?
Lakewood-Amedex Biotherapeutics Inc. (LABT) has negative shareholder equity of -$2.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.